Division of Cardiology and Cardiac Catheterization Laboratories, Showa University Northern Yokohama Hospital, 35-1, Chigasaki-Chuo, Tsuzuki, Yokohama, 224-8503, Japan.
ESC Heart Fail. 2018 Feb;5(1):87-94. doi: 10.1002/ehf2.12221. Epub 2017 Oct 2.
Few studies have reported the impact of high-dose loop diuretics at discharge on prognosis in Japanese patients with heart failure (HF). Our purpose was to assess the relationship between the dose of loop diuretics at discharge and cardiovascular mortality in patients with HF.
We enrolled decompensated HF patients who were admitted to our hospital between March 2010 and March 2015, and compared HF patients who received high-dose loop diuretics at discharge (HD group) with low-dose loop diuretics at discharge (LD group) with regard to risk of cardiovascular mortality, and all-cause mortality. High-dose loop diuretic was defined as ≥40 mg/day of oral furosemide at discharge. A total of 215 patients were enrolled to the study. The median follow-up duration was 641 days. All-cause and cardiovascular mortality were significantly lower in the LD group than in the HD group (10.4% vs. 31.6%, P < 0.001; 2.2% vs. 24.6%, P < 0.001, respectively). High-dose loop diuretics were associated with cardiovascular mortality in multivariate Cox proportional hazards model (hazard ratio, 16.06, 95% confidence interval 3.457 to 116.8; P < 0.001). The largest area under the receiver operating characteristic curve (0.85) for cardiovascular death was obtained with a threshold of 40 mg furosemide.
High-dose loop diuretic use at discharge was one of the predictors of cardiovascular mortality in patients with HF. An oral furosemide dose of 40 mg daily may be defined as 'high-dose' loop diuretics in Japanese patients with chronic HF.
鲜有研究报道大剂量袢利尿剂出院时对心力衰竭(HF)日本患者预后的影响。本研究旨在评估 HF 患者出院时袢利尿剂剂量与心血管死亡率之间的关系。
我们纳入了 2010 年 3 月至 2015 年 3 月期间因失代偿性 HF 入院的患者,并比较了出院时接受大剂量袢利尿剂(HD 组)与低剂量袢利尿剂(LD 组)HF 患者的心血管死亡率和全因死亡率。大剂量袢利尿剂定义为出院时口服呋塞米≥40mg/天。共纳入 215 例患者。中位随访时间为 641 天。LD 组全因死亡率和心血管死亡率均显著低于 HD 组(10.4%比 31.6%,P<0.001;2.2%比 24.6%,P<0.001)。多变量 Cox 比例风险模型显示,大剂量袢利尿剂与心血管死亡率相关(危险比,16.06,95%置信区间 3.457 至 116.8;P<0.001)。心血管死亡的受试者工作特征曲线下面积最大(0.85)的截断值为 40mg 呋塞米。
HF 患者出院时使用大剂量袢利尿剂是心血管死亡率的预测因素之一。在日本慢性 HF 患者中,40mg 呋塞米的日剂量可定义为“大剂量”袢利尿剂。